Published in Food and Drug Law Weekly, June 25th, 2004
The study showed that G17DT immunization was capable of raising functional antibodies to gastrin 17 in patients with gastric adenocarcinoma. Immunization was well tolerated with no evidence of autoimmune reaction or development of immunological tolerance by repeated immunization. A multicenter phase III trial is ongoing testing G17DT in combination with the chemotherapeutic gemcitabine for the treatment of patients with advanced pancreatic cancer.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.